Question explored with the scientific record
What are the most effective treatments for fungal toenails and what danger do they pose to the liver?
The short version: oral terbinafine is the most effective drug for common fungal toenail infections, but it carries real liver risks, and topical options are far safer though less effective.
The evidence here is a mixed bag of manufacturer-funded trials and small independent studies. The 1998 double-blind trial of 378 patients, funded by the drug maker, found terbinafine 250 mg daily for 12 weeks achieved mycologic cure in 73% of patients at 48 weeks, compared to 46% for itraconazole [3]. A 2002 systematic review confirmed terbinafine as the most effective oral option, with cure rates around 72% [1]. A 2022 Pakistani trial of 100 patients claimed pulse itraconazole beat continuous terbinafine (86% vs 64% effective cure), but that study had no blinding and reported no safety data at all [2]. The older, better-designed trial says the opposite.
The liver danger is real and dose-dependent. A 2014 safety review of oral ketoconazole found liver enzyme elevations in 17.5% of onychomycosis patients and overt hepatitis in 3% [6]. For terbinafine, the same review found a lower rate: about 16 liver injuries per 100,000 patients, compared to 36 for itraconazole and 49 for ketoconazole [6]. But "lower" is not "safe." A 2025 study of itraconazole in 103 patients found elevated liver enzymes in 2.9% and dyspeptic symptoms in 11.6% [7]. These are not rare events.
Topical efinaconazole 10% is the safer alternative. A 2025 pooled analysis of two phase 3 trials in older adults found complete cure in 13.6% of patients at 52 weeks, versus 3.6% with placebo [4]. That is a low cure rate, but the safety profile was essentially identical to placebo [4]. No liver toxicity. No systemic effects. The trade-off is clear: you trade efficacy for safety.
| Treatment | Cure rate (approx.) | Liver risk | Duration |
|---|---|---|---|
| Terbinafine 250 mg daily | 62-73% at 48 weeks [1, 3] | ~16 per 100,000 serious injury [6] | 12 weeks |
| Itraconazole pulse | 45-86% (varies by study) [2, 3] | ~36 per 100,000 [6] | 12 weeks (pulsed) |
| Efinaconazole 10% topical | 13-18% at 52 weeks [4, 5] | None detected [4] | 48 weeks daily |
| Ketoconazole oral | Not recommended | 49 per 100,000; 3% hepatitis [6] | Avoid |
For mild to moderate infections, start with topical efinaconazole. It will not work for everyone, but it will not hurt your liver. For severe or resistant cases, terbinafine is the best oral option, but you need baseline liver function tests and monitoring during treatment. Do not take oral antifungals without a doctor checking your liver enzymes first.
My call: for most people, topical efinaconazole is the right first choice despite low cure rates, because the liver risk from oral drugs is not trivial. Reserve oral terbinafine for confirmed severe cases with liver monitoring. Confidence: moderate.
Sources used 7
-
Oral Treatments for Toenail Onychomycosis
This systematic review evaluates the efficacy of oral treatments for toenail onychomycosis, concluding that terbinafine is the most effective option, while highlighting the need for standardized definitions of clinical cure and noting potential biases due to pharmaceutical fundi…
DOI: 10.1001/archderm.138.6.811 -
Comparative Study Between Pulse Therapy with Oral Itraconazole Versus Continuous Oral Terbinafine Therapy for Treatment of Onychomycosis
In a randomized controlled trial of 100 patients with dermatophyte onychomycosis, pulse oral itraconazole achieved effective cure in 86% versus 64% with continuous oral terbinafine at 48 weeks, a statistically significant difference.
DOI: 10.53350/pjmhs20221612745 -
Twelve weeks of continuous oral therapy for toenail onychomycosis caused by dermatophytes: A double-blind comparative trial of terbinafine 250 mg/day versus itraconazole 200 mg/day
A multicenter, double-blind randomized trial comparing 12 weeks of oral terbinafine 250 mg daily versus itraconazole 200 mg daily in adults with dermatophyte-caused toenail onychomycosis, showing superior mycologic and clinical cure at 48 weeks with terbinafine and good tolerabi…
DOI: 10.1016/s0190-9622(98)70486-4 -
Efficacy and Safety of Efinaconazole 10% Topical Solution for Onychomycosis Treatment in Older Adults
In a pooled post hoc analysis of two phase 3 RCTs, efinaconazole 10% topical solution improved onychomycosis cure rates versus vehicle in adults aged ≥65 years, with acceptable safety.
DOI: 10.25251/skin.10.supp.567 -
Efinaconazole Topical Solution, 10%: Formulation Development Program of a New Topical Treatment of Toenail Onychomycosis
This study presents the formulation development program for efinaconazole topical solution, 10%, aimed at providing effective transungual delivery for the treatment of toenail onychomycosis, demonstrating superior efficacy compared to existing treatments.
DOI: 10.1002/jps.24459 -
Drug safety assessment of oral formulations of ketoconazole
A comprehensive drug-safety review of oral ketoconazole formulations highlighting hepatotoxicity, endocrine effects, drug interactions, post-marketing surveillance findings, and regulatory actions that curtailed its use in favor of safer antifungals.
DOI: 10.1517/14740338.2015.983071 -
EVALUATION OF THE EFFECTIVENESS OF INTRIZOL IN THE TREATMENT OF FUNGAL INFECTIONS
Itraconazole (Intrizol) demonstrated high effectiveness and safety in treating fungal infections among 103 patients, with 78.6% overall complete recovery and particularly strong results for dermatophytosis and candidiasis, though lower efficacy for onychomycosis and systemic myc…
DOI: 10.64582/ivit.uz.334